Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS.
Hieken TJ, et al. Among authors: montane hn.
Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8.
Nat Commun. 2024.
PMID: 38365756
Free PMC article.
Clinical Trial.